Berger T - Search Results

1

Smoking is a risk factor for early conversion to clinically definite multiple sclerosis.

Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly E, Munger K, Deisenhammer F, Ascherio A, Berger T. Di Pauli F, et al. Among authors: berger t. Mult Scler. 2008 Sep;14(8):1026-30. doi: 10.1177/1352458508093679. Epub 2008 Jul 16. Mult Scler. 2008. PMID: 18632775

2

[Clinical aspects and diagnosis of multiple sclerosis].

Berger T, Deisenhammer F. Berger T, et al. Wien Med Wochenschr. 1996;146(19-20):504-13. Wien Med Wochenschr. 1996. PMID: 9082650 Review. German.

3

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Among authors: berger t. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

4

Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.

Kaser A, Deisenhammer F, Berger T, Tilg H. Kaser A, et al. Among authors: berger t. Lancet. 1999 Apr 24;353(9162):1413-4. doi: 10.1016/S0140-6736(99)00622-4. Lancet. 1999. PMID: 10227230 No abstract available.

5

Increased expression of apolipoprotein D following experimental traumatic brain injury.

Franz G, Reindl M, Patel SC, Beer R, Unterrichter I, Berger T, Schmutzhard E, Poewe W, Kampfl A. Franz G, et al. Among authors: berger t. J Neurochem. 1999 Oct;73(4):1615-25. doi: 10.1046/j.1471-4159.1999.0731615.x. J Neurochem. 1999. PMID: 10501208 Free article.

6

Cladribine treatment of a patient with hairy cell leukemia and concomitant multiple sclerosis.

Hilbe W, Berger T, Konwalinka G, Thaler J. Hilbe W, et al. Among authors: berger t. Acta Haematol. 1999;102(2):99-100. doi: 10.1159/000040978. Acta Haematol. 1999. PMID: 10529514

7

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Among authors: berger t. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

8

A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells.

Mayringer I, Reindl M, Berger T. Mayringer I, et al. Among authors: berger t. J Immunol Methods. 2000 Feb 21;235(1-2):33-40. doi: 10.1016/s0022-1759(99)00208-2. J Immunol Methods. 2000. PMID: 10675755

9

A comparative study of the relative bioavailability of different interferon beta preparations.

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Among authors: berger t. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.

10

Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.

Berger T, Reindl M. Berger T, et al. J Neural Transm Suppl. 2000;(60):351-60. doi: 10.1007/978-3-7091-6301-6_25. J Neural Transm Suppl. 2000. PMID: 11205153 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,148 results

Search Page

Filters